An independent guide to cash-pay care. Every price is dated and sourced.

How we check
Wellchosen Health

How long Mounjaro takes to work and how much weight people lose

Mounjaro is a type 2 diabetes medicine, not a weight-loss drug, and its trials report averages that individual results can fall above or below. In the 40-week SURPASS-1 trial, people on Mounjaro lost an average of 6.3 to 7.8 kg (about 14 to 17 pounds) while A1C fell 1.7 to 1.8 points [1]. When the same medicine was studied for weight management as Zepbound, adults without diabetes on 15 mg lost an average of 20.9% of body weight at 72 weeks [2].

Updated Oct 17, 2026By the Wellchosen Health editorial team

Medical review: pending. A licensed clinician has not yet reviewed this page.

Mounjaro results are the blood sugar and body weight changes measured in clinical trials of Mounjaro (tirzepatide) described in its FDA label.

Approved for
Type 2 diabetes (age 10+) and heart risk reduction in T2D [1]
A1C drop vs semaglutide 1 mg
2.0 to 2.3 points vs 1.9 at 40 weeks [1]
Weight change (SURPASS-1, 40 weeks)
-6.3 kg (5 mg) to -7.8 kg (15 mg) [1]
Half-life
About 5 days [1]
First approved
May 13, 2022 [3]

How Mounjaro works

Mounjaro contains tirzepatide, which activates two hormone receptors, GIP and GLP-1 [1]. It boosts insulin release and lowers glucagon when blood sugar is high, and it delays stomach emptying [1]. The label's main goal is lower blood sugar; weight change was recorded in the trials as a secondary result. For a comparison with single-hormone medicines, see Ozempic vs Mounjaro.

Is Mounjaro approved for weight loss?

No. Mounjaro is approved for blood sugar control in adults and children 10 and older with type 2 diabetes, and to lower major cardiovascular events in high-risk adults with type 2 diabetes. The use in children was added to the label in December 2025 and the heart use in August 2026 [1]. Using Mounjaro only to lose weight is off-label. Zepbound, the same medicine, was approved for chronic weight management on November 8, 2023 [4]. Mounjaro was first approved on May 13, 2022 [3]. The Mounjaro vs Zepbound page explains the label differences.

What the Mounjaro trials found

Mounjaro label trial results in adults with type 2 diabetes (40 weeks)
TrialDoseA1C changeWeight change
SURPASS-1 (vs placebo)Placebo-0.1-1.0 kg
SURPASS-15 mg-1.8-6.3 kg
SURPASS-110 mg-1.7-7.0 kg
SURPASS-115 mg-1.7-7.8 kg
SURPASS-2 (vs semaglutide 1 mg)Semaglutide 1 mg-1.9Not shown here
SURPASS-25 / 10 / 15 mg-2.0 / -2.2 / -2.3Not shown here
Source: Mounjaro prescribing information, Section 14 [1]. A1C in percentage points; SURPASS-2 baseline A1C was 8.3%. We did not have SURPASS-2 weight figures from the label text available to us.

In SURPASS-2, 79% of people on semaglutide 1 mg reached an A1C under 7%, vs 82% to 86% on Mounjaro [1]. Fasting glucose fell by 49 mg/dL on semaglutide and 55 to 60 mg/dL on Mounjaro [1].

What tirzepatide did in weight-management trials (Zepbound)

Zepbound's label trials show what tirzepatide does when studied for weight. In adults without diabetes (SURMOUNT-1), average weight change at 72 weeks was -15.0% on 5 mg, -19.5% on 10 mg and -20.9% on 15 mg, vs -3.1% on placebo [2]. In adults with type 2 diabetes, it was -12.8% on 10 mg and -14.7% on 15 mg, vs -3.2% on placebo [2]. People with diabetes lost less on average. In SURMOUNT-5, tirzepatide averaged -20.2% vs -13.7% on semaglutide at 72 weeks [5]. See Zepbound results.

How long Mounjaro takes to work

The label does not name a start date. Everyone begins on 2.5 mg once weekly, and the dose can rise by 2.5 mg after at least 4 weeks on the current dose [1]; the steps are on Mounjaro dosage. Trials measured results at 40 weeks for blood sugar and 72 weeks for weight [1] [2]. Appetite timing is not described. Tirzepatide's half-life is about 5 days [1], which is what makes once-weekly dosing work.

Why some people lose less, or gain

Trial averages hide a range. In SURMOUNT-1, 85% to 91% of people lost at least 5% of their weight, which means roughly 1 in 10 did not [6]. In Zepbound's trials, adults with type 2 diabetes lost less on average than adults without it (14.7% vs 20.9% on 15 mg) [2]. Dose matters too: the Zepbound label calls 2.5 mg a starting dose that is not meant for maintenance [7]. Mounjaro's label instead says to raise the dose when more blood sugar control is needed [1]. Insulin and some other medicines can also affect weight. If you are not losing weight, ask your prescriber whether your dose, your medicine or your diagnosis fits your goal. Trial results are averages, not promises.

Is Mounjaro safe, and how long do people stay on it?

Mounjaro carries a boxed warning about thyroid C-cell tumors seen in rats, plus warnings on pancreatitis, gallbladder disease, kidney injury and low blood sugar [1]; see Mounjaro side effects. There is no maximum treatment length on the label. Weight tends to return when tirzepatide ends: in SURMOUNT-4, the group moved to placebo after 36 weeks gained back 14.0% of body weight over the next year, while the group that continued lost a further 5.5% [8]. More on stopping Mounjaro and on eating habits in what to eat on Mounjaro.

Before you start

Do not use Mounjaro with a personal or family history of medullary thyroid carcinoma or MEN 2 [1]. Stop and call your prescriber for severe stomach pain that will not go away [1]. Call 911 for throat swelling or trouble breathing.

Compare Mounjaro prices

On price, Lilly's list figure is $1,112.16 per 28-day box of four pens [9]. Its savings card can bring that down to $25 for people whose commercial plan covers Mounjaro, or to as low as $499 a month for people whose commercial plan does not; it cannot be used by the uninsured or by government plan members, and it expires December 31, 2026 [10]. Prices checked October 17, 2026. Compare channels on Mounjaro cost or see how to get tirzepatide online.

Questions people ask

How does Mounjaro work?

Tirzepatide activates GIP and GLP-1 receptors, raising insulin and lowering glucagon when blood sugar is high, and slowing stomach emptying [1].

Is Mounjaro FDA approved for weight loss?

No. It is approved for type 2 diabetes in people 10 and older and for heart risk reduction in high-risk adults with type 2 diabetes [1]. Zepbound is the tirzepatide brand approved for weight management [4].

How much weight can you lose on Mounjaro?

In SURPASS-1, average loss at 40 weeks was 6.3 kg (5 mg) to 7.8 kg (15 mg) [1]. In Zepbound's trial in adults with type 2 diabetes, it was 12.8% to 14.7% at 72 weeks [2]. These are averages.

How long does it take for Mounjaro to work?

The label gives no start date. Dosing starts at 2.5 mg weekly, with increases after at least 4 weeks, and trials measured results at 40 weeks [1].

Why am I not losing weight on Mounjaro?

Results vary. In SURMOUNT-1, roughly 1 in 10 people lost less than 5% [6], and people with diabetes lost less on average in Zepbound trials [2]. Ask your prescriber about your dose and goals.

How long does Mounjaro stay in your system?

Tirzepatide's elimination half-life is about 5 days [1].

Can I stay on 2.5 mg Mounjaro for weight loss?

The Zepbound label calls 2.5 mg a starting dose not intended for maintenance [7]. Mounjaro's label says to raise the dose when more blood sugar control is needed [1]. Ask your prescriber.

How long has Mounjaro been on the market?

FDA approved Mounjaro on May 13, 2022 [3].

How long can you be on Mounjaro?

The label sets no maximum length. In SURMOUNT-4, people who stopped tirzepatide regained 14.0% of body weight over a year [8].

Sources

10 cited
  1. Mounjaro (tirzepatide) injection prescribing information. DailyMed, U.S. National Library of Medicine, Aug 2026.
  2. Zepbound prescribing information, NDA 217806 (PDF). U.S. Food and Drug Administration, Apr 2026.
  3. Drug Trials Snapshots: Mounjaro. U.S. Food and Drug Administration, May 13, 2022.
  4. FDA approves new medication for chronic weight management. U.S. Food and Drug Administration, Nov 8, 2023.
  5. SURMOUNT-5 trial, tirzepatide vs semaglutide (Aronne et al., NEJM 2025), PubMed record. PubMed, National Library of Medicine, May 11, 2025.
  6. SURMOUNT-1 trial of tirzepatide in adults with obesity (Jastreboff et al., NEJM 2022), PubMed record. PubMed, National Library of Medicine, Jun 4, 2022.
  7. Zepbound (tirzepatide) injection prescribing information. DailyMed, U.S. National Library of Medicine, Aug 2026.
  8. SURMOUNT-4 randomized withdrawal trial of tirzepatide (Aronne et al., JAMA 2024), PubMed record. PubMed, National Library of Medicine, Jan 1, 2024.
  9. Mounjaro frequently asked questions. Eli Lilly and Company, Oct 17, 2026.
  10. Mounjaro savings resources. Eli Lilly and Company, Oct 17, 2026.

This page is general information, not medical advice. Talk with a licensed clinician about your own care.

Compare Mounjaro prices